First Time Loading...

DiaMedica Therapeutics Inc
NASDAQ:DMAC

Watchlist Manager
DiaMedica Therapeutics Inc Logo
DiaMedica Therapeutics Inc
NASDAQ:DMAC
Watchlist
Price: 2.59 USD 2.37% Market Closed
Updated: May 2, 2024

DiaMedica Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

DiaMedica Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
DiaMedica Therapeutics Inc
NASDAQ:DMAC
Operating Income
-$21.3m
CAGR 3-Years
-19%
CAGR 5-Years
-26%
CAGR 10-Years
-11%
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$9.3B
CAGR 3-Years
32%
CAGR 5-Years
2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is DiaMedica Therapeutics Inc's Operating Income?
Operating Income
-21.3m USD

Based on the financial report for Dec 31, 2023, DiaMedica Therapeutics Inc's Operating Income amounts to -21.3m USD.

What is DiaMedica Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-11%

Over the last year, the Operating Income growth was -52%. The average annual Operating Income growth rates for DiaMedica Therapeutics Inc have been -19% over the past three years , -26% over the past five years , and -11% over the past ten years .